Nonsteroidal aromatase inhibitors

Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. [17]

Nonsteroidal aromatase inhibitors

nonsteroidal aromatase inhibitors

Media:

nonsteroidal aromatase inhibitorsnonsteroidal aromatase inhibitorsnonsteroidal aromatase inhibitorsnonsteroidal aromatase inhibitorsnonsteroidal aromatase inhibitors

http://buy-steroids.org